Rezolute Prices $100 Million Financing For Its Low-Blood-Sugar Drug's Commercialization Preparations
The company expects about $93.5 million after offering costs as preliminary ersodetug study findings await complete analysis.
Rezolute, which develops rare-disease treatments for dangerously low blood sugar, priced financing Friday expected to bring in about $100 million before costs. The company said in Monday's SEC filing that it plans to use the money alongside existing cash to prepare ersodetug for commercialization.
Cash For An Unapproved Treatment
Rezolute estimates it will receive about $93.5 million after underwriting charges and offering expenses. Working capital and general corporate spending are also among the intended uses, and the company expects the offering to close on or about Monday.
Ersodetug, its lead candidate, is an antibody delivered intravenously. Rezolute is studying it in children with congenital hyperinsulinism and in patients whose hyperinsulinism is caused by tumors. The condition involves excess insulin activity that can cause persistent, dangerously low blood sugar.
The company has no approved products. Its expanded access program supplies ersodetug to patients unable to participate in a clinical trial. Research and development spending totaled about $53.8 million for the fiscal year ended June 30, 2026.
13 Participants Met The Response Threshold
Preliminary findings from the late-stage tumor hyperinsulinism study met the main efficacy goal, the company said. That goal measures how much patients can reduce their need for intravenous glucose.
Among 16 participants, 13 reached the response threshold and 12 stopped intravenous glucose entirely. Three participants are still in the pivotal study period, so the findings remain preliminary.
Shares And Pre-Funded Warrants
The financing includes 22,040,976 common shares priced at $3.87 each. Certain investors are buying pre-funded warrants covering up to 3,800,000 shares—a right to buy stock with almost the entire purchase price paid upfront.
The warrants cost $3.869 each, with another $0.001 per share payable upon exercise. They can be exercised after issuance but carry no voting rights themselves. Issuing common shares, including shares obtained through warrant exercise, increases the share count that existing holders own a portion of.
Frazier Life Sciences, the investor leading the financing, participated with new and existing funds, according to the company's pricing release. Morgan Stanley, Guggenheim Securities and Cantor are the joint book-running managers selling the offering. H.C. Wainwright and Jones are lead managers; Maxim Group and Lake Street Capital Markets are co-managers.
Rezolute expects complete study results, including statistical analysis of the main efficacy goal, by mid-December 2026.
Sources
- 8-K Filing — Rezolute, Inc. (RZLT) — SEC EDGAR
- Exhibit tm2627558d9_ex99-1.htm — Rezolute, Inc. 8-K exhibit — SEC EDGAR
- Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization — Yahoo Finance
- Rezolute Announces Pricing of Approximately $100 Million — globenewswire.com